• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

LKC Technologies introduces RETeval

Article

LKC Technologies recently debuted RETeval, a handheld diabetic retinopathy (DR) screening device that enables any healthcare provider to screen for and detect sight-threatening DR.

Gaithersburg, MD-LKC Technologies recently debuted RETeval, a handheld diabetic retinopathy (DR) screening device that enables any healthcare provider to screen for and detect sight-threatening DR. The World Health Organization estimates more than 75% of people who have diabetes for more than 20 years will have some form of DR. The Centers for Disease Control estimates that better DR detection can reduce blindness by up to 50%-60%.

RETeval is a functional test of the retina to assess the ischemic level of the retina, which, based upon published literature, correlates well to DR and other ischemic diseases such as central retinal vein occlusion, birdshot retinopathy, and others. RETeval is fast, easy to use, and provides immediate results at a very low cost without dilation.

LKC believes that any healthcare provider, from physicians’ offices to community clinics to mobile clinics in third-world countries, could easily use the RETeval and be highly effective in alerting patients to their risk of diabetic retinopathy.

The RETeval is CE marked and approved in Canada and Japan, and is being used in a number of countries such as Indonesia, Malaysia, Japan, and the U.K. LKC is developing the clinical data necessary to submit for FDA approval in the United States. 

Related Videos
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Robert Weiss, former CEO and President of The Cooper Companies, Inc. (left) and Optometry Times' Assistant Managing Editor Emily Kaiser Maharjan Image Credit ©Optometry Times
© 2024 MJH Life Sciences

All rights reserved.